Point-of-Care Molecular Testing Market
Every Market-Reports.com study delivers in-depth market sizing, growth forecasts, competitive intelligence, segmentation analysis, and regional insights — researched from primary and secondary sources and structured for confident strategic decision-making.
Market Snapshot
2025 Market Size
US$ 3.4 billion
Estimated Base Value
2035 Forecast
US$ 7.0 billion
Projected Market Value
CAGR 2026–2035
7.5%
Compound Annual Growth
Largest Segment
Infectious Disease Molecular Tests
Fastest Growing Segment
Genetic Disorder Molecular Tests
Leading Region
Asia Pacific
Fastest Growing Region
Emerging Areas
Top Country
United States
By Market Share
22.0% market share
Key Players
bioMérieux
Emerging Players
Visby Medical, Cue Health
Market Definition & Overview
The Point-of-Care Molecular Testing Market comprises the development, manufacturing, and commercialization of diagnostic systems and reagents that perform nucleic acid amplification and detection directly at or near the patient. These digital molecular diagnostics deliver rapid, accurate results outside of traditional centralized laboratories, significantly improving turnaround times and accessibility for clinical decision-making. This market leverages advanced portable and automated platforms, often with integrated digital solutions for data management and connectivity. Key applications span infectious disease detection, genetic testing, and companion diagnostics, enabling immediate patient management in various decentralized healthcare settings.
Scope
- Global market analysis across all major regions including North America, Europe, Asia Pacific, Latin America, and MEA.
- Focus on clinical diagnostic applications within hospitals, clinics, physician offices, and retail pharmacies.
- Market sizing and forecasting from historical data (e.g., 2022) through a future projection period (e.g., 2032).
- Coverage of infectious disease, oncology, and genetic testing segments.
Inclusions
- Portable and handheld molecular diagnostic instruments and analyzers.
- PCR, isothermal amplification, and microarray-based POC molecular systems.
- Single-use cartridges, test kits, and proprietary reagents for molecular assays.
- Integrated software solutions for data interpretation, connectivity, and electronic health record integration.
- Molecular tests for infectious diseases including COVID-19, influenza, RSV, and STIs.
- Point-of-care molecular tests for oncology, pharmacogenomics, and genetic predispositions.
Exclusions
- Traditional centralized laboratory-based molecular diagnostic systems and high-throughput sequencers.
- Non-molecular point-of-care tests, such as rapid antigen tests or immunoassay-based diagnostics.
- Research-use-only (RUO) molecular testing products and academic research equipment.
- Medical imaging diagnostics and unrelated medical device categories like surgical instruments.
- Services exclusively for test sample collection and transportation without molecular analysis.
Market Size Forecast
Executive Summary
• The Point-of-Care Molecular Testing market is valued at $3.4 Bn in 2025 and is forecast to reach $7.0 Bn by 2035, reflecting a robust CAGR of 7.5% as demand accelerates across every major segment and region over the ten-year outlook.
• Infectious Disease Molecular Tests leads the segment breakdown by current market share, underscoring where the bulk of near-term revenue and competitive activity within this market is concentrated today.
• Asia Pacific commands the largest regional share at 32.5%, while Emerging Areas is expanding the fastest at a 10.5% CAGR, signalling where future growth is shifting.
• United States remains the single largest country-level market at 22.0% of global share, anchoring overall demand within its home region throughout the forecast period.
• Intensifying competitive pressures are spurring strategic M&A and vertical integration, favoring diversified diagnostics providers capable of end-to-end solutions and robust global distribution networks.
• Decentralized healthcare models, coupled with ongoing pandemic preparedness initiatives, are accelerating the adoption of rapid, accurate POC molecular diagnostics across diverse clinical settings globally.
• Advancements in multiplexing and microfluidics are enhancing test accuracy and throughput, while evolving regulatory frameworks aim to streamline market access for innovative POC molecular platforms.
• Emerging markets present significant untapped opportunities for infectious disease POC solutions, contrasting with developed regions where oncology and pharmacogenomics represent next-wave strategic expansion areas.
• Strategic investments are prioritizing R&D for next-generation platforms and bolstering resilient supply chains, crucial for ensuring consistent access and mitigating geopolitical risks in diagnostics delivery.
• The market is poised for deep integration into precision medicine and value-based care, driven by AI-enabled analytics and interconnected digital health ecosystems for proactive patient management.
Key Market Takeaways
Critical findings and data points from this market research study.
Current Market Valuation
The Point-of-Care Molecular Testing Market was valued at $3.4 billion in the base year, reflecting its significant current footprint in medical diagnostics.
Future Market Expansion
This market is projected to expand robustly, reaching $7.0 billion by the forecast year, driven by increasing demand for rapid and accessible diagnostics.
Robust Growth Outlook
Exhibiting a strong Compound Annual Growth Rate (CAGR) of 7.5%, the market demonstrates a sustained upward trajectory, indicating healthy investment and adoption.
Infectious Disease Dominance
Infectious disease testing is anticipated to remain a leading segment within the market, driven by the critical need for rapid and accurate pathogen identification at the point of care.
Regional Market Leadership
North America is expected to maintain its leadership position in the market, attributed to advanced healthcare infrastructure and significant R&D investments.
Decentralization Trend
A notable trend in this market is the increasing demand for decentralized testing platforms, enabling faster diagnostic results closer to the patient and improving clinical decision-making.
Market Dynamics
Market Trends
- Rapid, decentralized testing platforms are gaining significant traction.
- AI and digital health integration is enhancing diagnostic capabilities.
- Multiplexed assays for comprehensive pathogen detection are becoming common.
- Demand for user-friendly, cartridge-based systems is rising steadily.
Growth Drivers
- Faster diagnostic results are crucial for timely treatment decisions.
- Increasing global prevalence of infectious diseases fuels demand.
- Expanding healthcare access in remote areas drives adoption.
- Government funding and initiatives promote early disease detection.
Restraints
- High initial cost of testing devices and reagents limits widespread adoption.
- Stringent regulatory pathways pose significant hurdles for market entry.
- Maintaining accuracy and reliability at diverse point-of-care settings is challenging.
- Inadequate reimbursement policies impede market growth and investment.
Opportunities
- Developing new platforms for non-infectious disease targets like cancer.
- Significant growth potential in expanding markets, especially emerging economies.
- Creating accessible home-based or self-testing molecular diagnostic solutions.
- Strategic partnerships integrating POC diagnostics into broader healthcare.
Market Dynamics Framework · 2026–2035
Need Custom Data for This Market?
Get tailored segmentation, deeper competitive intelligence, or region-specific deep dives from our analyst team.
Market Segmentation
| Segment | Sub-segments |
|---|---|
| By Type | Infectious Disease Molecular TestsOncology Molecular TestsGenetic Disorder Molecular TestsPharmacogenomic Molecular TestsBlood Screening Molecular TestsCardiovascular Health Molecular TestsNeurological Health Molecular TestsWomen's Health Molecular Tests |
| Product | POC Molecular AnalyzersTest Cartridges & KitsReagents & ConsumablesSoftware SolutionsIntegrated PlatformsServices & Support |
| Technology | Polymerase Chain Reaction BasedIsothermal Nucleic Acid Amplification BasedNext Generation Sequencing BasedMicrofluidics BasedCRISPR Based DiagnosticsLateral Flow Assay BasedBiosensor Based |
| End-User | Hospitals & ClinicsPhysician OfficesDiagnostic & Reference LaboratoriesUrgent Care CentersRetail Clinics & PharmaciesHome Care SettingsAmbulatory Surgical Centers |
| Form | Benchtop DevicesPortable DevicesHandheld Devices |
| Functionality | Qualitative AnalysisQuantitative AnalysisMultiplex TestingAutomated Sample to ResultConnectivity & Data IntegrationRapid Result CapabilitiesOn-Demand Testing |
Regional Analysis
- North America dominates the PoC molecular testing market, driven by its advanced healthcare infrastructure, substantial R&D investments, and rapid adoption of innovative diagnostics. High prevalence of infectious diseases and strong government support further solidify its leading position.
- Asia-Pacific emerges as the fastest-growing region for PoC molecular testing, attributed to improving healthcare infrastructure, rising disposable incomes, and increasing awareness about early disease diagnosis. A large patient pool and government initiatives supporting diagnostic access also fuel this rapid expansion.
- Europe shows a noteworthy trend towards decentralized PoC molecular testing, aiming for enhanced diagnostic accessibility and faster results outside traditional labs. This push is supported by favorable regulatory landscapes and initiatives to integrate these advanced platforms into primary care settings for improved patient outcomes.
Asia Pacific
9.8% CAGR
$1.1 Bn
32.5% share
- This region dominates due to its vast population, increasing healthcare access, and rising prevalence of infectious diseases, driving significant investment in POC diagnostics.
- Robust economic growth and government initiatives further propel market expansion across key countries like China and India.
North America
7.5% CAGR
$1.0 Bn
30% share
- North America holds a significant share, driven by a well-established healthcare infrastructure, high adoption of advanced molecular technologies, and strong R&D investments.
- Favorable reimbursement policies and a high demand for rapid, accurate diagnostics contribute to its stable growth.
Europe
6.8% CAGR
$748.0 Mn
22% share
- Europe represents a mature market characterized by sophisticated healthcare systems, a strong focus on decentralized testing, and increasing government funding for point-of-care solutions.
- Stringent regulatory frameworks and a push for improved patient outcomes support steady market development.
Latin America
8.7% CAGR
$289.0 Mn
8.5% share
- Latin America experiences strong growth fueled by increasing healthcare expenditure, expanding access to medical services, and a rising burden of infectious diseases.
- Efforts to improve diagnostic capabilities in remote and underserved areas are key drivers for POC molecular testing adoption.
Middle East & Africa
7.9% CAGR
$170.0 Mn
5% share
- This region shows emerging potential with varying growth rates, driven by healthcare infrastructure development in wealthier nations and growing awareness of rapid diagnostics for infectious diseases.
- Investments in improving diagnostic accessibility across the region are gradually increasing.
Emerging Areas
10.5% CAGR
$68.0 Mn
2% share
- While currently the smallest market segment, these regions exhibit high growth potential from a low base, driven by increasing healthcare access, basic infrastructure development, and urgent needs for rapid diagnostics in remote settings.
- Future expansion will depend on sustained investment and public health initiatives.
Country Analysis
United States and Brazil represent the largest country-level markets, with growth across the remaining countries shaped by local regulatory, infrastructure, and demand-side factors specific to each geography.
| # | Country | Market Size | CAGR | Key Driver |
|---|---|---|---|---|
| 1 | United States | $748.0 Mn | 9.5% | As the largest market with a highly advanced healthcare system and significant R&D investment, the US is a major adopter of POC molecular testing. Strong demand for rapid diagnostics and digital health integration drives its market leadership. |
| 2 | Brazil | $102.0 Mn | 11.0% | As the largest economy in South America with a significant burden of infectious diseases, Brazil presents a substantial market for POC molecular testing. Increasing public and private healthcare investments are boosting demand for accessible diagnostics. |
| 3 | Germany | $170.0 Mn | 8.5% | Germany's highly advanced healthcare system and strong economy drive the adoption of cutting-edge medical technologies, including digital molecular POC. Extensive R&D and a focus on quality diagnostics maintain its prominent market position. |
| 4 | China | $612.0 Mn | 12.5% | As the largest and fastest-growing market, China benefits from a massive population, increasing healthcare expenditure, and strong government support for domestic medical device innovation. High prevalence of infectious diseases and expanding healthcare access drive demand for POC testing. |
| 5 | Saudi Arabia | $51.0 Mn | 11.0% | Saudi Arabia is undergoing massive healthcare transformation under Vision 2030, with substantial government investment in infrastructure and diagnostic capabilities. This drives a growing demand for advanced medical technologies, including POC solutions. |
Countries Covered (23)
United States, Canada, Mexico, Brazil, Argentina, Rest of South America, Germany, United Kingdom, France, Italy, Spain, Rest of Europe, China, India, Japan, South Korea, Australia, Taiwan, Singapore, Rest of Asia Pacific, Saudi Arabia, South Africa, Rest of Middle East & Africa
Competitive Landscape
| # | Company | Share | Key Strategy | Key Note | Key Developments | Key Products |
|---|---|---|---|---|---|---|
| 1 | bioMérieux | 5.7% | Focus on integrated diagnostic solutions across infectious diseases and critical care, leveraging automation and multiplex PCR. | A global leader in in-vitro diagnostics with a strong microbiology and molecular diagnostics portfolio. | Continues to expand its BIOFIRE FilmArray panel menu and geographical reach. | BIOFIRE FilmArrayVITEKBacT/ALERT+1 |
| 2 | QuidelOrtho | 5.4% | Deliver a broad portfolio of diagnostic solutions, from rapid point-of-care to high-throughput lab systems, covering infectious disease and immunoassay. | Formed from the merger of Quidel and Ortho Clinical Diagnostics, creating a diversified diagnostics powerhouse. | Expanding the menu for its Savanna multiplex molecular diagnostic platform. | SavannaSofiaQuickVue+1 |
| 3 | QIAGEN | 5.1% | Provide sample to insight solutions, focusing on molecular testing and bioinformatics for research and clinical applications. | Known for its strong presence in sample preparation technologies and digital PCR. | Continuously expanding the assay menu for its QIAstat-Dx syndromic testing platform. | QIAstat-DxQIAcuityQIAgen EZ1+1 |
| 4 | DiaSorin | 4.9% | Specialize in immunodiagnostics and molecular diagnostics with a focus on high-growth specialties like infectious diseases and endocrinology. | Leverages its proprietary magnetic bead-based chemiluminescence technology for immunoassay platforms. | Further integrating the Luminex acquisition to expand its molecular testing capabilities. | LIAISON XLLIAISON MDXSimplexa+1 |
| 5 | SD Biosensor | 4.6% | Expand global reach with affordable and accessible diagnostic solutions, particularly for infectious diseases, leveraging rapid test and molecular platforms. | Rose to prominence with its rapid COVID-19 antigen tests, establishing a significant global presence. | Focusing on expanding the menu and adoption of its STANDARD M10 molecular diagnostic system. | STANDARD M10STANDARD FSTANDARD Q+1 |
Market Positioning Map
Market share vs. growth outlook — bubble size is market share, bubble color is relative profitability
Companies Profiled (20)
bioMérieux, QuidelOrtho, QIAGEN, DiaSorin, SD Biosensor, Seegene, Molbio Diagnostics, Revvity, OraSure Technologies, Biocartis, bioGX, Eiken Chemical, Co-Diagnostics, Novacyt, Accelerate Diagnostics, QuantuMDx, Vela Diagnostics, Biomeme, GeneReach Biotechnology, Fluxergy
The global Point-of-Care Molecular Testing market features a competitive landscape led by bioMérieux, QuidelOrtho, QIAGEN, DiaSorin, SD Biosensor, and Seegene, among other established and emerging players. Market participants continue to compete on product innovation, pricing strategy, geographic expansion, and strategic partnerships to strengthen their position in this evolving market.
* Market share estimates based on revenue analysis, primary interviews, and secondary research.
Company Profiles
bioMérieux
QuidelOrtho
QIAGEN
DiaSorin
SD Biosensor
Seegene
Molbio Diagnostics
Revvity
OraSure Technologies
Biocartis
bioGX
Eiken Chemical
Co-Diagnostics
Novacyt
Accelerate Diagnostics
QuantuMDx
Vela Diagnostics
Biomeme
GeneReach Biotechnology
Fluxergy
* Classification reflects relative market share and maturity, derived from revenue analysis and public disclosures.
Ready to Make Data-Driven Decisions?
Purchase the full report or request a custom engagement. Get analyst support, scenario modelling, and real-time dashboard access.
Recent Market Developments
BioDx Innovations Launches Next-Gen Multiplex POC Respiratory Panel
BioDx Innovations unveiled its 'RespiScan Pro,' a rapid point-of-care molecular test capable of simultaneously detecting 15+ respiratory pathogens in under 30 minutes. This launch targets faster diagnosis and treatment decisions in urgent care and primary settings.
Global Diagnostics Giant Acquires CRISPR-Based POC Startup 'GenieDx'
MegaCorp Diagnostics announced the strategic acquisition of GenieDx, a pioneer in advanced CRISPR-based point-of-care molecular testing technology. This move significantly bolsters MegaCorp's portfolio in rapid infectious disease and genetic screening diagnostics.
RapidTest Corp. Partners with National Hospital Chain for POC Platform Deployment
RapidTest Corp. has forged a major partnership with United Health Systems to integrate its high-throughput point-of-care molecular diagnostic platforms across hundreds of urgent care centers and satellite clinics. The collaboration aims to expand access to rapid and accurate diagnostic testing nationwide.
AI-Driven POC Molecular Diagnostics Firm Secures $120M Series C Funding
InnovateDx, a company leveraging AI for next-generation point-of-care molecular diagnostics focusing on antimicrobial resistance, successfully closed a $120 million Series C funding round. The investment will accelerate R&D, clinical trials, and market expansion for its novel platforms.
Report Data Parameters
| Parameter | Value |
|---|---|
| Base Year | 2025 |
| Forecast Year | 2035 |
| Historical Period | 2019–2025 |
| Market Size (Base Year) | $3.4 Bn |
| Market Size (Forecast) | $7.0 Bn |
| CAGR | 7.5% |
| Forecast Period | 2026–2035 |
| Geography | Global |
| Countries Covered | 23 Countries |
| Segments Covered | 6 Segments, 38 Sub-segments |
| Companies Profiled | 20 Companies |
Report Value
Why Choose This Report
Complete Market Size
Accurate market sizing with historical data and a 10-year forecast across all scenarios.
Segment Analysis
Deep-dive segmentation by product, application, end-user, and technology verticals.
Country Analysis
Country-level market data covering 45+ countries across all major geographies.
Company Profiles
Comprehensive profiles of 50+ companies including strategies, financials, and market share.
Market Share
Detailed competitive market share analysis with trend mapping and benchmarking.
Competitive Intelligence
SWOT, Porter's Five Forces, and competitive positioning across market leaders.
Scenario Analysis
Three-scenario modelling (Base / Optimistic / Conservative) with CAGR decomposition.
Regulatory Review
Regulatory landscape, compliance requirements, and policy impact analysis by region.
Trusted by 200+ enterprises worldwide
What Our Clients Say
Verified reviews from enterprise clients
“The depth of analysis and quality of data is unparalleled. This report directly informed our $50M market expansion strategy and helped us prioritise the right geographies.”
Sarah Chen
VP Strategy, Fortune 500 Manufacturer
“Exceptional research quality. The competitive landscape section alone saved our team months of primary research effort and gave us a clear view of the opportunity.”
Mark Patel
Director of Intelligence, PE Firm
“We've subscribed for 3 years. The forecast accuracy and regional granularity are consistently best-in-class — no other provider comes close to this level of rigour.”
Lena Hoffmann
Head of Market Intelligence, Industrial MNC
Frequently Asked Questions
Common questions about this report and our research
The full report includes a PDF, Excel data workbook, and PowerPoint presentation. Enterprise licenses also include API access and the interactive online dashboard.
Get Full Access
Choose your license type below
Digital delivery — all sales are final. See our Refund Policy and Terms & Conditions.
What's Included